Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Greetings, and welcome to the INmune Bio Second Quarter 2025 Earnings Call. [Operator Instructions] As a reminder, this conference is being ...

Company to Host Conference Call Today, August 7th, at 4:30pm ETBOCA RATON, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company ...

INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.

Explore INmune Bio's Fair Values from the Community and select yours. Even when a business is losing money, it's possible for shareholders to make money if they buy a good busines ...

Explore INmune Bio's Q2 2025 earnings call: new CEO, strategic shifts, XPro's Alzheimer's pause, CORDStrom advancements, and a focus on partnerships.

INmune Bio Inc. (NASDAQ:INMB) saw its stock jump 28% on Monday after announcing that its Phase I/II trial evaluating INKmune™ ...

To learn more, please visit www.inmunebio.com . INmune Bio Contact: David Moss, CFO (858) 964-3720 [email protected] Media Contact: Antenna Group Holly Dugan (201) 465-8019 INmuneBio ...

OmniScience and INmune Bio (INMB) announced a partnership to revolutionize operations for INmune Bio’s global Phase 2 Alzheimer’s disease, or AD, clinical trial using OmniScience’s product ...

According to TipRanks, Farmer is an analyst with an average return of -3.3% and a 41.90% success rate. Farmer covers the Healthcare sector, focusing on stocks such as Urogen Pharma, Inmune Bio, and ...

INmune Bio has a promising drug pipeline with no drugs in production. While this increases the risk, it also greatly increases the upside. Read more here.

INmune Bio Contact: David Moss, CFO (858) 964-3720 [email protected] Investor Contact: Jason Nelson, Core IR (516) 842-9614 x-823 ...